Neuroendocrine neoplasms of the appendix: Characterization of 335 patients referred to the Copenhagen NET Center of Excellence.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
06 2021
Historique:
received: 03 11 2020
revised: 13 01 2021
accepted: 03 02 2021
pubmed: 17 2 2021
medline: 12 10 2021
entrez: 16 2 2021
Statut: ppublish

Résumé

Neuroendocrine neoplasms (NEN) of the appendix are often incidentally discovered after appendectomy. Appropriate management is debated. The purpose was to characterize a cohort of 335 appendix NEN and evaluate the risk of recurrence. Retrospective collection of data from 335 patients referred to the Neuroendocrine Tumor Center at Rigshospitalet 2000-2019. Appendix goblet cell carcinoids and mixed neuroendocrine non-neuroendocrine neoplasms were excluded. Patients were followed until December 31st, 2019. No patients were lost to follow-up. Sixty-three percent of the patients were female. The median (range) age at diagnosis was 34 (9-92) years. Median follow-up was 66 (1-250) months. Median tumor size was 7 (1-45) mm with 10 (3%) tumors >20 mm. In 18 specimens (5%) resection margins were positive. Mesoappendiceal invasion was found in 113 (35%). Sixty-three (19%) patients underwent right-sided completion hemicolectomy (RHC) after appendectomy according to ENETS guidelines. Among these, 11 (17%) had lymph node metastases in the resected tissue. Further, one patient who underwent initial RHC due to colonic adenocarcinoma had lymph node metastases. All lymph node metastases were detected in patients with serotonin positive tumors. No patients with glucagon positive tumors (n = 85) had lymph node metastases. Mesoappendiceal invasion >3 mm and positive resection margins were associated with presence of lymph node metastases. No recurrences were recorded. Following ENETS guidelines may lead to overtreatment of patients with respect to completion RHC. The risk of over- and undertreatment needs to be further evaluated.

Identifiants

pubmed: 33589240
pii: S0748-7983(21)00088-3
doi: 10.1016/j.ejso.2021.02.005
pii:
doi:

Substances chimiques

Chromogranin A 0
Serotonin 333DO1RDJY
Glucagon 9007-92-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1357-1363

Informations de copyright

Copyright © 2021 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Auteurs

Pernille Holmager (P)

ENETS Neuroendocrine Tumor Centre of Excellence, Rigshospitalet, Copenhagen University Hospital, Denmark; Dept. of Endocrinology, Rigshospitalet, Copenhagen University Hospital, Denmark. Electronic address: Holmager@dadlnet.dk.

Gro Linno Willemoe (GL)

ENETS Neuroendocrine Tumor Centre of Excellence, Rigshospitalet, Copenhagen University Hospital, Denmark; Dept. of Pathology, Rigshospitalet, Copenhagen University Hospital, Denmark.

Kirstine Nielsen (K)

ENETS Neuroendocrine Tumor Centre of Excellence, Rigshospitalet, Copenhagen University Hospital, Denmark; Dept. of Surgery, Rigshospitalet, Copenhagen University Hospital, Denmark.

Veronica Grøndahl (V)

ENETS Neuroendocrine Tumor Centre of Excellence, Rigshospitalet, Copenhagen University Hospital, Denmark; Dept. of Surgery, Rigshospitalet, Copenhagen University Hospital, Denmark.

Marianne Klose (M)

ENETS Neuroendocrine Tumor Centre of Excellence, Rigshospitalet, Copenhagen University Hospital, Denmark; Dept. of Endocrinology, Rigshospitalet, Copenhagen University Hospital, Denmark.

Mikkel Andreassen (M)

ENETS Neuroendocrine Tumor Centre of Excellence, Rigshospitalet, Copenhagen University Hospital, Denmark; Dept. of Endocrinology, Rigshospitalet, Copenhagen University Hospital, Denmark.

Seppo W Langer (SW)

ENETS Neuroendocrine Tumor Centre of Excellence, Rigshospitalet, Copenhagen University Hospital, Denmark; Dept. of Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark.

Carsten Palnæs Hansen (CP)

ENETS Neuroendocrine Tumor Centre of Excellence, Rigshospitalet, Copenhagen University Hospital, Denmark; Dept. of Surgery, Rigshospitalet, Copenhagen University Hospital, Denmark.

Andreas Kjær (A)

ENETS Neuroendocrine Tumor Centre of Excellence, Rigshospitalet, Copenhagen University Hospital, Denmark; Dept. of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen University Hospital, Denmark.

Birgitte H Federspiel (BH)

ENETS Neuroendocrine Tumor Centre of Excellence, Rigshospitalet, Copenhagen University Hospital, Denmark; Dept. of Pathology, Rigshospitalet, Copenhagen University Hospital, Denmark.

Ulrich Knigge (U)

ENETS Neuroendocrine Tumor Centre of Excellence, Rigshospitalet, Copenhagen University Hospital, Denmark; Dept. of Endocrinology, Rigshospitalet, Copenhagen University Hospital, Denmark; Dept. of Surgery, Rigshospitalet, Copenhagen University Hospital, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH